Melanoma by the State: North Carolina
North Carolina is known as the Tar Heel state, and the term “tar heel” dates back to the state’s…
Melanoma by the State
12/08/2021
Melanoma by the State: North Carolina
North Carolina is known as the Tar Heel state, and the term “tar heel” dates back to the state’s…
|
09/24/2021
Melanoma by the State: Oregon
Let’s start with some fun facts about Oregon: Oregon boasts the deepest lake in the U.S., Crater Lake, with a…
|
03/08/2021
Melanoma By The State: Texas
Melanoma, don’t mess with Texas! That’s essentially the rallying cry of volunteers, medical institutions, foundations, and other interested groups…
|
11/12/2020
Melanoma by the State: North Dakota
North Dakota Wants Residents to Protect Their Skin North Dakota is a farming and ranching state, with 39.1 million acres…
|
01/23/2020
Melanoma By The State: Colorado
In 1876, one hundred years after the signing of the Declaration of Independence, Colorado became the 38th state of…
|
11/14/2019
Melanoma by the State: Montana
Dubbed “Big Sky Country,” Montana is the fourth largest state in total landmass, comprising vast rolling prairie land in…
|
09/19/2019
Melanoma By The State: Tennessee
The state of Tennessee is famous for the Grand Ole Opry, Graceland, and the Great Smoky Mountains. It’s also known…
|
03/19/2019
Melanoma By The State: Arizona
Arizona touts itself as being home to three of the sunniest cities in the United States—Yuma, Phoenix, and Tucson—and for…
|
01/14/2019
Melanoma By The State: Nevada
The seventh largest state in land area in the United States, Nevada boasts a rugged landscape filled with desert valleys…
|
08/30/2018
Melanoma By The State: Vermont
Vermont is a state known for national and state forests, majestic snow-covered mountains, delicious maple syrup, and Ben and Jerry’s…
|
Recent Posts
Jun. 05, 2026
Fifth Annual Evening in Memory of Valerie Guild
Jun. 05, 2026
Results for darovasertib in combination with crizotinib in first line HLA*A2:01-negative metastatic uveal melanoma met the study’s primary objective
Jun. 05, 2026
Encouraging results with anzutresgene autoleucel in patients with uveal melanoma and other melanoma subtypes
Jun. 05, 2026
Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors
Jun. 05, 2026